Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma

Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma

Purpose:To investigate the survival outcomes and toxicities associated with the addition of nimotuzumab to concurrent chemoradiotherapy (CCRT) in locally advanced nasopharyngeal carcinoma (LANPC) patients who received induction chemotherapy (IC).Methods:Patients with stage III-IVA nasopharyngeal car...

Full description

Bibliographic Details
Main Authors:	Run-Jie Wang, Rui-Quan Ke, Yi-Feng Yu, Guan-Zhong Lu, San-Gang Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Pharmacology
Subjects:	nasopharyngeal carcinoma anti-EGFR nimotuzumab outcome radiotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1366853/full

Similar Items

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
by: Jing-Feng Zong, et al.
Published: (2021-11-01)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
by: Zhi Yang, et al.
Published: (2023-11-01)

Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
by: Lili Wang, et al.
Published: (2023-02-01)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
by: Tania Crombet Ramos, et al.
Published: (2020-05-01)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
by: Zhaodong Fei, et al.
Published: (2020-10-01)

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
by: Xinmao Song, et al.
Published: (2019-07-01)

The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
by: Wang Zhi-Qiang, et al.
Published: (2019-11-01)

Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China
by: Tian X, et al.
Published: (2020-05-01)

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
by: Huang JF, et al.
Published: (2018-07-01)

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials
by: Yan Yuan, et al.
Published: (2022-10-01)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
by: Yanping Huang, et al.
Published: (2023-09-01)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
by: Qiuji Wu, et al.
Published: (2021-10-01)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
by: Tania Crombet, et al.
Published: (2011-04-01)

Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer
by: Chen W, et al.
Published: (2019-09-01)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
by: Yan Li, et al.
Published: (2022-08-01)

Fragmentation of Nimotuzumab for Preparation of 125I-F(ab’)2-Nimotuzumab as a Precursor for Preparing 125I-F(ab’)2-Nimotuzumab-NLS Radiopharmaceutical for Cancer Therapy
by: R.D. Haryuni, et al.
Published: (2014-04-01)

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study
by: Jing Hu, et al.
Published: (2022-07-01)

Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
by: Greta Garrido, et al.
Published: (2017-10-01)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
by: Zhao Lei, et al.
Published: (2012-12-01)

Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis
by: Hao Peng, et al.
Published: (2018-03-01)

The Clinical Outcomes and Toxicities of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Rui Zou, et al.
Published: (2021-02-01)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
by: Jiraporn Setakornnukul, et al.
Published: (2018-03-01)

Preparation of (177Lu-DOTA)n-PAMAM-[Nimotuzumab-F(ab’)2] as a Therapeutic Radioimmunoconjugate for EGFR Overexpressed Cancer Treatment
by: Titis Sekar Humani, et al.
Published: (2017-12-01)

Multi-center Clinical Study of Nimotuzumab Combined with PF Regimen in Induction Treatment of Locally Advanced Nasopharyngeal Carcinoma
by: LU Ying, et al.
Published: (2019-04-01)

The Double-Edge Role of the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy in the Treatment of Nasopharyngeal Carcinoma
by: Liang ZG, et al.
Published: (2020-02-01)

Deletion of concurrent chemotherapy on the basis of sequential chemoradiotherapy for non‐metastatic stage T4 nasopharyngeal carcinoma in IMRT era
by: Yuming Zheng, et al.
Published: (2024-02-01)

Safety of nimotuzumab following clinical trials in head and neck epithelial tumors
by: Oneyda Clapé-Laffita, et al.
Published: (2021-05-01)

Nimotuzumab y gemcitabina en el tratamiento del cáncer de páncreas y metástasis esplénica
by: Ángel Piriz Momblant, et al.
Published: (2019-07-01)

Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
by: Henrry Diaz, et al.
Published: (2022-07-01)

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
by: Wendy Bernhard, et al.
Published: (2021-03-01)

Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis
by: Ji-Jin Yao, et al.
Published: (2017-03-01)

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease
by: Niurys de Castro-Suárez, et al.
Published: (2020-11-01)

Temperature and Stretching Effects on Complementarity Determining Regions (CDRs) Conformation and Stability of Nimotuzumab F(ab)-Fragment
by: T.S. Humani, et al.
Published: (2015-04-01)

Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis
by: Yu Zhang, et al.
Published: (2022-12-01)

Nimotuzumab Significantly Enhances Chemosensitivity of PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro
by: Yu XIAO, et al.
Published: (2015-02-01)

Supervivencia libre de progresión en pacientes portadores de meningiomas vacunados con nimotuzumab
by: Héctor Figueredo Acosta, et al.
Published: (2018-01-01)

Humoral characteristics of head and neck tumors in patients treated with nimotuzumab
by: Lisandra Roca Serra, et al.
Published: (2018-05-01)

Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study
by: Xia WX, et al.
Published: (2019-11-01)

The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
by: Bi-Cheng Wang, et al.
Published: (2020-05-01)

Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy
by: Man Ao, et al.
Published: (2023-12-01)